Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of mefatinib versus gefitinib as first-line treatment for EGFR-mutated advanced non-squamous non-small cell lung cancer
ChiCTR2000028763Phase 3Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mifanertinib and gefitinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Progression-free survival. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
mifanertinibgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000028763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028763.